Skip to main content

Images are character representations of Demodex mites.

illustrated demodex mites at the beach

Treat the Eyelid Mite Party: Discover the XDEMVY® Effect

demodex mites hiding behind XDEMVY bottle

One drop per eye, twice a day (~12 hours apart), for 6 weeks.

XDEMVY Targets and Kills the Mites  That Cause Demodex Blepharitis (DB)

XDEMVY was created specifically to treat Demodex blepharitis

XDEMVY is the first and only FDA-approved treatment for DB.1,2

demodex mites hiding behind XDEMVY bottle

One drop per eye, twice a day (~12 hours apart), for 6 weeks.

CAN YOU SEE THE DIFFERENCE XDEMVY HAS ON DB?

Witness the real impact XDEMVY has on eyelids with DB for yourself! Try to successfully match up eyelids before treatment with XDEMVY to the same eyelids after treatment.

Real patients below with DB used XDEMVY twice daily, in each eye, for 6 weeks. Results may vary.

THE RULES

Before XDEMVY

After XDEMVY

Now that you’ve matched all the BEFORE and AFTER images successfully, submit your name and email to learn more about XDEMVY.

EYES MATCHED:  /5

Please enter your name and email address to receive more information about XDEMVY.
All fields are required.

See How XDEMVY Breaks Up the Mite Parties

  • One drop per eye, twice a day, approximately 12 hours apart, in just 6 weeks

    In 2 combined studies, 50% of patients had a reduction of crusties (collarettes) and  60% of patients had their Demodex mites completely wiped out.3*

    Before XDEMVY

    eyelid afflicted with demodex blepharitis db

    After XDEMVY

    eyelid cured of demodex blepharitis db

    Images are of an actual patient who participated in clinical trials for Tarsus Pharmaceuticals. Results may vary.
    Real patient with DB used XDEMVY twice daily, in each eye for 6 weeks.

  • Designed for patient comfort

    ~90% of patients in both trials reported XDEMVY eye drops as neutral to very comfortable to use.3†

  • Stay on top of your treatment

    It’s important to use XDEMVY for the full 6 weeks.

  • Reduce eyelid redness

    Patients using XDEMVY for DB may see eyelid redness gone in just 6 weeks.1,2

XDEMVY for Demodex blepharitis was evaluated in 2 pivotal trials of 833 patients (415 received XDEMVY).2,4,5
Trial 1: When taken twice daily in each eye for 6 weeks, XDEMVY reduced collarettes to 2 or less for the upper eyelid in 44% of patients (N=209) at Day 43; XDEMVY eradicated mites (mite density of 0 mites/lash) in 68% of patients (N=212) at Day 43.
Trial 2: When taken twice daily in each eye for 6 weeks, XDEMVY reduced collarettes to 2 or less for the upper eyelid in 55% of patients (N=193) at Day 43; XDEMVY eradicated mites (mite density of 0 mites/lash) in 50% of patients (N=203) at Day 43.

All visits averaged.3

demodex mite saying oh no with text that reads party’s over
References

References: 1. XDEMVY Pivotal Trial Data Presentation. Tarsus Pharmaceuticals Inc. 2. XDEMVY. Prescribing Information. Tarsus Pharmaceuticals Inc; 2023. 3. Yeu E, Paauw JD, Vollmer P, et al. Safety and efficacy of lotilaner ophthalmic solution (0.25%) in treating Demodex blepharitis: pooled analysis of two pivotal trials. Ophthalmol Ther. 2025;14(3):555-571. 4. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2) [published online ahead of print, 2023 Jun 5]. Ophthalmology. 2023;S0161-6420(23)00392-5. 5. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). Cornea. 2023;42(4):435-443.

References: 1. XDEMVY Pivotal Trial Data Presentation. Tarsus Pharmaceuticals Inc. 2. XDEMVY. Prescribing Information. Tarsus Pharmaceuticals Inc; 2023. 3. Yeu E, Paauw JD, Vollmer P, et al. Safety and efficacy of lotilaner ophthalmic solution (0.25%) in treating Demodex blepharitis: pooled analysis of two pivotal trials. Ophthalmol Ther. 2025;14(3):555-571. 4. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2) [published online ahead of print, 2023 Jun 5]. Ophthalmology. 2023;S0161-6420(23)00392-5. 5. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). Cornea. 2023;42(4):435-443.